174 related articles for article (PubMed ID: 33912510)
1. Combined α-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7-positive prostate cancer cells.
Yoshizawa A; Takahara K; Saruta M; Zennami K; Nukaya T; Fukaya K; Ichino M; Fukami N; Niimi A; Sasaki H; Kusaka M; Suzuki M; Sumitomo M; Shiroki R
Prostate Int; 2021 Mar; 9(1):18-24. PubMed ID: 33912510
[TBL] [Abstract][Full Text] [Related]
2. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
[TBL] [Abstract][Full Text] [Related]
3. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
Takahara K; Azuma H; Sakamoto T; Kiyama S; Inamoto T; Ibuki N; Nishida T; Nomi H; Ubai T; Segawa N; Katsuoka Y
Anticancer Res; 2009 Jul; 29(7):2497-505. PubMed ID: 19596919
[TBL] [Abstract][Full Text] [Related]
4. Novel 2-arylthiopropanoyl-CoA inhibitors of α-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.
Yevglevskis M; Nathubhai A; Wadda K; Lee GL; Al-Rawi S; Jiao T; Mitchell PJ; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Bioorg Chem; 2019 Nov; 92():103263. PubMed ID: 31536953
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
Liang J; Wang L; Poluben L; Nouri M; Arai S; Xie L; Voznesensky OS; Cato L; Yuan X; Russo JW; Long HW; Brown M; Chen S; Balk SP
Cancer Lett; 2021 Oct; 519():172-184. PubMed ID: 34256096
[TBL] [Abstract][Full Text] [Related]
6. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
8. Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2201-2210. PubMed ID: 28741117
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Diagnosis Using Urine Sediment Analysis-Based α-Methylacyl-CoA Racemase Score: A Single-Center Experience.
Ji J; Chen X; Xu Y; Cao Z; Xu H; Kong C; Wang F; Sun Y
Cancer Control; 2019; 26(1):1073274819887697. PubMed ID: 31793344
[TBL] [Abstract][Full Text] [Related]
10. Trifluoroibuprofen inhibits α-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models.
Festuccia C; Gravina GL; Mancini A; Muzi P; Cesare ED; Kirk R; Smith M; Hughes S; Gibson R; Lian LY; Ricevuto E; Carnell AJ
Anticancer Agents Med Chem; 2014; 14(7):1031-41. PubMed ID: 24712326
[TBL] [Abstract][Full Text] [Related]
11. Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase
Shapovalova M; Davydova J; Henzler C; Daniel M; Dehm SM; Warlick CA; LeBeau AM
Oncotarget; 2018 Nov; 9(94):36693-36704. PubMed ID: 30613352
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections.
Krzyzanowska A; Lippolis G; Helczynski L; Anand A; Peltola M; Pettersson K; Lilja H; Bjartell A
J Histochem Cytochem; 2016 May; 64(5):311-22. PubMed ID: 27026295
[TBL] [Abstract][Full Text] [Related]
13. alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Kuefer R; Varambally S; Zhou M; Lucas PC; Loeffler M; Wolter H; Mattfeldt T; Hautmann RE; Gschwend JE; Barrette TR; Dunn RL; Chinnaiyan AM; Rubin MA
Am J Pathol; 2002 Sep; 161(3):841-8. PubMed ID: 12213712
[TBL] [Abstract][Full Text] [Related]
14. Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Lee H; Kim M; Kim SH; Tran Q; Kong G; Kim C; Kwon SH; Park J; Park JB; Park S; Park J
Front Oncol; 2020; 10():550673. PubMed ID: 33154941
[TBL] [Abstract][Full Text] [Related]
15. Alanine-Serine-Cysteine Transporter 2 Inhibition Suppresses Prostate Cancer Cell Growth In Vitro.
Saruta M; Takahara K; Yoshizawa A; Niimi A; Takeuchi T; Nukaya T; Takenaka M; Zennami K; Ichino M; Sasaki H; Kusaka M; Suzuki M; Sumitomo M; Shiroki R
J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143113
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
17. A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer.
Li Y; Chu Y; Shi G; Wang X; Ye W; Shan C; Wang D; Zhang D; He W; Jiang J; Ma S; Han Y; Zhao Z; Du S; Chen Z; Li Z; Yang Y; Wang C; Xu X; Wu H
Acta Pharm Sin B; 2022 Nov; 12(11):4165-4179. PubMed ID: 36386477
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
Marín-Aguilera M; Jiménez N; Reig Ò; Montalbo R; Verma AK; Castellano G; Mengual L; Victoria I; Pereira MV; Milà-Guasch M; García-Recio S; Benítez-Ribas D; Cabezón R; González A; Juan M; Prat A; Mellado B
Cells; 2020 Jan; 9(1):. PubMed ID: 31947623
[TBL] [Abstract][Full Text] [Related]
19. Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.
Hakozaki Y; Murata T; Yokoyama M; Matsushima H; Ogawa M; Masuda T; Hirai Y; Kume H
Urol Case Rep; 2018 Sep; 20():67-69. PubMed ID: 30009133
[TBL] [Abstract][Full Text] [Related]
20. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
